You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Treatment of Transplant Reperfusion with an Anti-CD47 Antibody

    SBC: VASCULOX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Organ transplantation is one of the great success stories of modern medicine. However, the supply of suitable organs lags far behind the need and many patients die while waitlisted for organs. Current practice involves donor preconditioning to stabilize organs and tissues for transplant in attempts to increase the supply of donor organs acceptable for transpl ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  2. Vascular Targeting for Imaging and Treatment of Benign Prostatic Hyperplasia

    SBC: ANDROBIOSYS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Benign Prostatic Hyperplasia/Hypertrophy is a major health problem in the United States, with one-in-three men having urologic problems. Currently available treatment modalities include alpha-blockers that do not affect the underlying pathologic process, and 5-alpha-reductase inhibitors that have significant systemic side-effects. We have discovered that human ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  3. Primary Xenografts of Human Tissue as Surrogates of Cancer In Situ

    SBC: ANDROBIOSYS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): AndroBioSys, Inc. is dedicated to the development of human tissue-based in vivo tools capable of selecting better targeted agents for clinical trials by improved preclinical testing. AndroBioSys has developed the technology for reproducible implantation of primary xenografts of benign and malignant human prostate and kidney tissue. Xenografts have been establis ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  4. Novel therapeutic for Alcoholic Liver Disease

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): Alcoholic Liver Disease (ALD) is a progressive liver disease that in advanced stages can result in cirrhosis and liver failure. ALD can be divided in various stages of development: (1) mild alcoholic liver injury, (2) steatosis, (3) alcoholic hepatitis, (4) alcoholic liver fibrosis and (5) cirrhosis. Liver fibrosis is a form of scar formation that is found in a ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  5. Small Molecule Therapeutics for Renal Disease

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): Diabetic and non-diabetic nephropathies and the Metabolic Syndrome are associated with chronic kidney disease (CKD) - a program comprising proteinuria, accumulation of profibrotic collagen in the renal interstitium and relentless decline in renal function. CKD remains an unsolved challenge for the nephrologist, as it almost inevitably leads to end-stage renal d ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  6. Phase I Study of BB3 in Dialysis Patients

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): Kidney transplantation is the most effective therapeutic modality for end-stage renal disease; it offers a better quality of life and a longer survival. Despite improvements in surgical and organ preservation techniques over the last decade, renal dysfunction and/or failure remains a significant problem following transplantation. Ischemia-reperfusion injury ass ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  7. Novel Therapeutic for Duchenne Muscular Dystrophy (DMD)

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): A significant body of literature indicates that Hepatocyte Growth Factor (HGF) via potent and direct anti-fibrotic activity protects many organs from the fibrosis-driven pathology. In addition, HGF has been shown to also promote muscle progenitor cells to proliferate to promote the regenerative capacity of the muscle in response to injury or significant work ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  8. Novel Neuroprotective/Restorative Therapy for Ischemic Stroke

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): Ischemic Stroke continues to be a major cause of morbidity and mortality in the United States. Currently approved thrombolytic therapy suffers for a narrow therapeutic window and clearly other therapeutic strategies are needed, such as neuroprotective or restorative agents. Unfortunately the quest for a therapeutic remains beset by a history of failed clinical ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  9. Therapeutic use of small-molecule HGF-mimetic for emphysema

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): Emphysema is a major cause of death and disability and afflicts approximately 2 million people. The disease cost more than 2.5 billion in annual health care expenses and causes or contributes to the death of 100,000 people each year in the United States alone. The disease is characterized by destruction of the alveolar wall, permanent enlargement of the airspa ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Neuroprotective/Anti-inflammatory Therapy for Ischemic Stroke

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): Stroke is leading cause of morbidity and mortality in the US. Research on the pathophysiological basis of stroke has produced new paradigms for prevention and treatment, but translation of these approaches into improved clinical outcomes has proved to be painfully slow. Preventive strategies focus primarily on reducing or controlling risk factors such as diabet ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government